



## CONSORT 2010 checklist of information to include when reporting a randomised trial\*

Section/Topic	Item No	Checklist item	Reported on Page Number/Line Number	Reported on Section/Paragraph
<b>Title and abstract</b>				
	1a	Identification as a randomised trial in the title	Page 1 line3	title
	1b	Structured summary of trial design, methods, results, and conclusions (for specific guidance see Table 2)	Page1-2, line 26-30	abstract /paragraph 1-2
<b>Introduction</b>				
Background and objectives	2a	Scientific background and explanation of rationale	page 2-3, line 58-76	introduction/paragraph 1-2
	2b	Specific objectives or hypotheses	page 3, line 80	introduction/paragraph 3
<b>Methods</b>				
Trial design	3a	Description of trial design (such as parallel, factorial) including allocation ratio	page 4, line 112	methods/ paragraph 2
	3b	Important changes to methods after trial commencement (such as eligibility criteria), with reasons	page 4, line 120	methods/ paragraph 2
Participants	4a	Eligibility criteria for participants	page 3, line 93	methods/ paragraph 1
	4b	Settings and locations where the data were collected	page 3, line 93	methods/ paragraph 1
Interventions	5	The interventions for each group with sufficient details to allow replication, including how and when they were actually administered	page 4, line 129	methods/ paragraph 3
Outcomes	6a	Completely defined pre-specified primary and secondary outcome measures, including how and when they were assessed	page 5, line 143	methods/ paragraph 4
	6b	Any changes to trial outcomes after the trial commenced, with reasons	page 5, line 143	methods/ paragraph 4
Sample size	7a	How sample size was determined	page 4, line 129	methods/ paragraph 3
	7b	When applicable, explanation of any interim analyses and stopping guidelines	page 3, line 93	methods/ paragraph 3
Randomisation:			page 3, line 98	methods/ paragraph 3
Sequence generation	8a	Method used to generate the random allocation sequence	page 3, line 93	methods/ paragraph 3
	8b	Type of randomisation; details of any restriction (such as blocking and block size)	page 4, line 100	methods/ paragraph 4
Allocation concealment mechanism	9	Mechanism used to implement the random allocation sequence (such as sequentially numbered containers), describing any steps taken to conceal the sequence until interventions were assigned	page 3, line 93	methods/ paragraph 3

Implementation	10	Who generated the random allocation sequence, who enrolled participants, and who assigned participants to interventions	page 3, line 99	methods/ paragraph 3
Blinding	11a	If done, who was blinded after assignment to interventions (for example, participants, care providers, those assessing outcomes) and how	page 4, line 105	methods/ paragraph 4
	11b	If relevant, description of the similarity of interventions	page 4, line 106	methods/ paragraph 4
Statistical methods	12a	Statistical methods used to compare groups for primary and secondary outcomes	page 4, line 104	methods/ paragraph 4
	12b	Methods for additional analyses, such as subgroup analyses and adjusted analyses	page 5, line 143	methods/ paragraph 4
<b>Results</b>				
Participant flow (a diagram is strongly recommended)	13a	For each group, the numbers of participants who were randomly assigned, received intended treatment, and were analysed for the primary outcome	page 5, line 150	results/ paragraph 1
	13b	For each group, losses and exclusions after randomisation, together with reasons	page 5, line 152	results/ paragraph 1
Recruitment	14a	Dates defining the periods of recruitment and follow-up	page 5, line 159	results/ paragraph 1
	14b	Why the trial ended or was stopped	page 5, line 155	results/ paragraph 1
Baseline data	15	A table showing baseline demographic and clinical characteristics for each group	page 9, line 276	results/ paragraph 1
Numbers analysed	16	For each group, number of participants (denominator) included in each analysis and whether the analysis was by original assigned groups	page 5, line 165	results/ paragraph 1
Outcomes and estimation	17a	For each primary and secondary outcome, results for each group, and the estimated effect size and its precision (such as 95% confidence interval)	page 5, line 160	results/ paragraph 1
	17b	For binary outcomes, presentation of both absolute and relative effect sizes is recommended	page 5, line 161	results/ paragraph 1
Ancillary analyses	18	Results of any other analyses performed, including subgroup analyses and adjusted analyses, distinguishing pre-specified from exploratory	page 5, line 161	results/ paragraph 1
Harms	19	All important harms or unintended effects in each group (for specific guidance see CONSORT for harms)	page 5, line 161	results/ paragraph 1
<b>Discussion</b>				
Limitations	20	Trial limitations, addressing sources of potential bias, imprecision, and, if relevant, multiplicity of analyses	page 5, line 168	discussion/ paragraph 1
Generalisability	21	Generalisability (external validity, applicability) of the trial findings	page 5, line 172	discussion/ paragraph 2
Interpretation	22	Interpretation consistent with results, balancing benefits and harms, and considering other relevant evidence	page 6, line 180	discussion/ paragraph 3
<b>Other information</b>				
Registration	23	Registration number and name of trial registry	page 3, line 93	methods/ paragraph 3

Protocol	24	Where the full trial protocol can be accessed, if available	page 4, line 99	methods/ paragraph 1
Funding	25	Sources of funding and other support (such as supply of drugs), role of funders	page 1, line 52	funding/ paragraph 1

\*We strongly recommend reading this statement in conjunction with the CONSORT 2010 Explanation and Elaboration for important clarifications on all the items. If relevant, we also recommend reading CONSORT extensions for cluster randomised trials, non-inferiority and equivalence trials, non-pharmacological treatments, herbal interventions, and pragmatic trials. Additional extensions are forthcoming: for those and for up to date references relevant to this checklist, see [www.consort-statement.org](http://www.consort-statement.org).

**Table 2 Items to include when reporting a randomized trial in a journal or conference abstract**

Item	Description	Reported on Page Number/Line Number	Reported on Section/Paragraph
Title	Identification of the study as randomized	Page 1 line3	title graph 1
Authors *	Contact details for the corresponding author	Page 1 line19	authors paragraph 1
Trial design	Description of the trial design (e.g. parallel, cluster, non-inferiority)	Page 1 line13	contributions paragraph 1
<b>Methods</b>			
Participants	Eligibility criteria for participants and the settings where the data were collected	page 3, line 93	methods/ paragraph 1
Interventions	Interventions intended for each group	page 3, line 95	methods/ paragraph 2
Objective	Specific objective or hypothesis	page 4, line 107	methods/ paragraph 2
Outcome	Clearly defined primary outcome for this report	page 4, line 105	methods/ paragraph 3
Randomization	How participants were allocated to interventions	page 5 line 140	methods/ paragraph 1
Blinding (masking)	Whether or not participants, care givers, and those assessing the outcomes were blinded to group assignment	page 4, line 100	methods/ paragraph 2
<b>Results</b>			
Numbers randomized	Number of participants randomized to each group	page 5, line 149	results/ paragraph 1
Recruitment	Trial status	page 5, line 153	results/ paragraph 2
Numbers analysed	Number of participants analysed in each group	page 5, line 151	results/ paragraph 3
Outcome	For the primary outcome, a result for each group and the estimated effect size and its precision	page 5, line 150	results/ paragraph 3
Harms	Important adverse events or side effects	page 5, line 161	results/ paragraph 1

Conclusions	General interpretation of the results	page 5, line 164	results/ paragraph 2
Trial registration	Registration number and name of trial register	page 5, line 163	results/ paragraph 1
Funding	Source of funding	page 5, line 161	results/ paragraph 2

*\* this item is specific to conference abstracts*

From: Hopewell S, Clarke M, Moher D, et al. CONSORT for reporting randomized controlled trials in journal and conference abstracts: explanation and elaboration. PLoS Med. 2008;5(1):e20

Article Information: <http://dx.doi.org/10.21037/apm-20-1532>

\*As the checklist was provided upon initial submission, the page number/line number reported may be changed due to copyediting and may not be referable in the published version. In this case, the section/paragraph may be used as an alternative reference.